Literature DB >> 9133455

Overexpression of folate binding protein in ovarian cancers.

G Toffoli1, C Cernigoi, A Russo, A Gallo, M Bagnoli, M Boiocchi.   

Abstract

The high affinity folate binding protein (FBP) is overexpressed in ovarian cancers. However, its role in the pathogenesis and biological behaviour of these neoplasms is not clearly understood. Using the monoclonal antibody (MAb) MOv 18 and cytofluorimetric analysis, we investigated FBP expression in frozen neoplastic tissues from 136 patients diagnosed with epithelial ovarian cancer. FBP values were compared with clinico-pathological characteristics (age, stage, histologic grade, histologic type, DNA ploidy, percentage of S-phase cells, and previous chemotherapeutic treatment). Some amount of FBP overexpression was observed in 122 of the 136 tumours examined. The overall mean value of FBP fluorescence index (FBP FI) was 5.6 (median 2.7; min 0.8--max, 78.9). By univariate analysis, FBP FI was overexpressed to a higher degree in ovarian neoplasms with high histologic grade, advanced stage, serous histology, aneuploid status, and high percentage of cells in S-phase. Of the total number (136) of cases, 106 had all the parameters assessed and were thus selected for stepwise selection procedure. The only significant independent variable was the percentage of S-phase cells, which accounted for about 31% of variance of FBP FI. Our results indicate that FBP is associated with parameters of biological aggressiveness in ovarian cancers.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9133455     DOI: 10.1002/(sici)1097-0215(19970422)74:2<193::aid-ijc10>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  123 in total

Review 1.  Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.

Authors:  Alicia Fernandez-Fernandez; Romila Manchanda; Anthony J McGoron
Journal:  Appl Biochem Biotechnol       Date:  2011-09-27       Impact factor: 2.926

2.  Folate-immunoglobulin G as an anticancer therapeutic antibody.

Authors:  Hong Li; Yanhui Lu; Longzhu Piao; Jun Wu; Xiaojuan Yang; Sri Vidya Kondadasula; William E Carson; Robert J Lee
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

3.  Folate, vitamin B(6) , vitamin B(12) , methionine and alcohol intake in relation to ovarian cancer risk.

Authors:  Holly R Harris; Daniel W Cramer; Allison F Vitonis; Mary DePari; Kathryn L Terry
Journal:  Int J Cancer       Date:  2011-11-08       Impact factor: 7.396

4.  Quantification of endocytosis using a folate functionalized silica hollow nanoshell platform.

Authors:  Sergio Sandoval; Natalie Mendez; Jesus G Alfaro; Jian Yang; Sharraya Aschemeyer; Alex Liberman; William C Trogler; Andrew C Kummel
Journal:  J Biomed Opt       Date:  2015-08       Impact factor: 3.170

5.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

6.  Role of farletuzumab in epithelial ovarian carcinoma.

Authors:  Danijela Jelovac; Deborah K Armstrong
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 7.  Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.

Authors:  Rongbao Zhao; Larry H Matherly; I David Goldman
Journal:  Expert Rev Mol Med       Date:  2009-01-28       Impact factor: 5.600

8.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

9.  Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients.

Authors:  Kimberly R Kalli; Matthew S Block; Pashtoon M Kasi; Courtney L Erskine; Timothy J Hobday; Allan Dietz; Douglas Padley; Michael P Gustafson; Barath Shreeder; Danell Puglisi-Knutson; Dan W Visscher; Toni K Mangskau; Glynn Wilson; Keith L Knutson
Journal:  Clin Cancer Res       Date:  2018-03-15       Impact factor: 12.531

10.  Synthesis, characterization, and in vitro assay of folic acid conjugates of 3'-azido-3'-deoxythymidine (AZT): toward targeted AZT based anticancer therapeutics.

Authors:  Anthony R Vortherms; Robert P Doyle; Dayuan Gao; Olivia Debrah; Patrick J Sinko
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2008-02       Impact factor: 1.381

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.